ABVC BioPharma, Inc.
ABVC
$0.911
$0.0354.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -96.42% | 224.51% | |||
| Total Other Revenue | -224.73% | -- | |||
| Total Revenue | -99.49% | 232.45% | |||
| Cost of Revenue | -100.00% | 50.00% | |||
| Gross Profit | -99.49% | 232.48% | |||
| SG&A Expenses | 0.96% | -71.40% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 369.23% | -- | |||
| Total Operating Expenses | 18.36% | -70.52% | |||
| Operating Income | -668.41% | 106.84% | |||
| Income Before Tax | 196.27% | 90.32% | |||
| Income Tax Expenses | -100.00% | 100.36% | |||
| Earnings from Continuing Operations | 195.98% | 89.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 291.97% | -120.12% | |||
| Net Income | 222.88% | 81.57% | |||
| EBIT | -668.41% | 106.84% | |||
| EBITDA | -600.41% | 107.66% | |||
| EPS Basic | 216.00% | 83.22% | |||
| Normalized Basic EPS | 260.91% | 79.40% | |||
| EPS Diluted | 187.00% | 77.78% | |||
| Normalized Diluted EPS | 260.91% | 79.40% | |||
| Average Basic Shares Outstanding | 6.44% | 9.57% | |||
| Average Diluted Shares Outstanding | 6.44% | 9.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||